title: [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
abstract: OBJECTIVE
  The most effective treatment for epithelial ovarian cancer is the combination of surgical operation and chemotherapy. Complete removal of the tumor is the key of surgical treatment; TP regimen (paclitaxel plus carboplatin) is the preference for postoperative chemotherapy, but its superiority is controversial. This study was to compare the efficacy of TP regimen and CBP regimen (cyclophosphamide, bleomycin plus carboplatin/cisplatin) on epithelial ovarian cancer.
  
  
  METHODS
  Clinical data of 125 patients with stage IIb-IV epithelial ovarian cancer, underwent optimal cytoreductive operation and received regular postoperative chemotherapy in Cancer Center of Sun Yat-sen University, were analyzed. Of the 125 patients, 65 were treated with CBP regimen, 60 were treated with TP regimen. The 3-year survival statuses and main adverse events were compared between the 2 groups.
  
  
  RESULTS
  The 3-year survival rates were 69.2% in CBP group and 75.3% in TP group (P=0.473); the 3-year tumor-free survival rates were 38.5% and 43.3%, respectively (P=0.580); the medians of progression-free survival time of the patients with recurrent disease were 12 months and 13 months, respectively (P=0.672). The comparisons of overall survival curves and tumor-free survival curves between the 2 groups showed no significant differences, too (P=0.285 and P=0.517). The comparisons of adverse effects between the 2 groups showed no significant differences except for neurologic toxicity.
  
  
  CONCLUSIONS
  TP regimen and CBP regimen have identical therapeutic effects when used as first-line chemotherapy regimen for epithelial ovarian cancer after optimal cytoreductive operation.
authors: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
authors: Ke-Fei
authors: KF
authors: Gao
authors: Fu-Yuan
authors: FY
authors: Liu
authors: Fu-Jin
authors: FJ
authors: Chen
authors: Yan-Ling
authors: YL
authors: Feng
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018282:Cystadenocarcinoma, Mucinous / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D013509:Gynecologic Surgical Procedures / Q000379:methods; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D015996:Survival Rate
chemical_list: D001761:Bleomycin; D003520:Cyclophosphamide; D016190:Carboplatin; D017239:Paclitaxel